董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Cynthia L. Lucchese | 女 | Director | 55 | 20.33万美元 | 未持股 | 2016-04-20 |
| Kieran T. Gallahue | 男 | Director | 53 | 33.18万美元 | 未持股 | 2016-04-20 |
| W. Anthony Vernon | 男 | Director | 60 | 31.67万美元 | 未持股 | 2016-04-20 |
| Frederic H. Moll | -- | Director | 64 | 18.60万美元 | 未持股 | 2016-04-20 |
| Lisa D. Earnhardt | 女 | President, Chief Executive Officer and Director | 46 | 217.23万美元 | 未持股 | 2016-04-20 |
| Dana G. Mead, Jr. | 男 | Director | 57 | 20.06万美元 | 未持股 | 2016-04-20 |
| Casey M. Tansey | 男 | Director | 58 | 18.58万美元 | 未持股 | 2016-04-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Charles S. McKhann | 男 | Chief Commercial Officer | 47 | 153.81万美元 | 未持股 | 2016-04-20 |
| David A. Lehman | 男 | General Counsel | 55 | 未披露 | 未持股 | 2016-04-20 |
| Jeryl L. Hilleman | 女 | Chief Financial Officer | 58 | 100.91万美元 | 未持股 | 2016-04-20 |
| David A. Lehman | 男 | General Counsel | 55 | 未披露 | 未持股 | 2016-04-20 |
| Lisa D. Earnhardt | 女 | President, Chief Executive Officer and Director | 46 | 217.23万美元 | 未持股 | 2016-04-20 |
| Richard E. Kaufman | 男 | Senior Vice President, Chief Operating Officer | 54 | 69.28万美元 | 未持股 | 2016-04-20 |
| James Stambaugh | 男 | Vice President, Clinical Affairs | 46 | 61.06万美元 | 未持股 | 2016-04-20 |
| Amy Wolbeck | 女 | Vice President, Regulatory Affairs and Quality | 43 | 未披露 | 未持股 | 2016-04-20 |
董事简历
中英对照 | 中文 | 英文- Cynthia L. Lucchese
-
Cynthia L. Lucchese， 2008年2月8日被选为高级副总裁和首席财务官。从2005年到2007年担任 Thoratec公司高级副总裁和首席财务官。在那之前，她在Guidant 公司（现在是波士顿技术公司的一部分）工作10年，担任多个高级金融职位，包括副总裁和风险官；企业总监和首席会计官；金融副总裁和Guidant销售公司行政总监。她之前曾在礼来公司和安永会计师事务所工作。
Cynthia L. Lucchese,served as Chief Strategy Officer for Penske Entertainment Corp (previously Hulman and Company), a subsidiary of Penske Corporation, from November 2020 until her retirement in February 2023, and she served as Chief Administrative Officer and Chief Financial Officer from November 2014 to November 2020. Previously, she was Senior Vice President and Chief Financial Officer of Hillenbrand (NYSE: HI) from 2008 to 2014. She also served from 2005 to 2007 as Senior Vice President and Chief Financial Officer of Thoratec (NASDAQ: THOR), a medical device company focused on treating advanced stage heart failure, and she held various senior financial positions with Guidant Corporation (NYSE: GDT), now a part of Boston Scientific, from 1994 to 2005. Ms. Lucchese earned her undergraduate degree in accounting and MBA from the Indiana University Kelley School of Business. - Cynthia L. Lucchese， 2008年2月8日被选为高级副总裁和首席财务官。从2005年到2007年担任 Thoratec公司高级副总裁和首席财务官。在那之前，她在Guidant 公司（现在是波士顿技术公司的一部分）工作10年，担任多个高级金融职位，包括副总裁和风险官；企业总监和首席会计官；金融副总裁和Guidant销售公司行政总监。她之前曾在礼来公司和安永会计师事务所工作。
- Cynthia L. Lucchese,served as Chief Strategy Officer for Penske Entertainment Corp (previously Hulman and Company), a subsidiary of Penske Corporation, from November 2020 until her retirement in February 2023, and she served as Chief Administrative Officer and Chief Financial Officer from November 2014 to November 2020. Previously, she was Senior Vice President and Chief Financial Officer of Hillenbrand (NYSE: HI) from 2008 to 2014. She also served from 2005 to 2007 as Senior Vice President and Chief Financial Officer of Thoratec (NASDAQ: THOR), a medical device company focused on treating advanced stage heart failure, and she held various senior financial positions with Guidant Corporation (NYSE: GDT), now a part of Boston Scientific, from 1994 to 2005. Ms. Lucchese earned her undergraduate degree in accounting and MBA from the Indiana University Kelley School of Business.
- Kieran T. Gallahue
-
Kieran T. Gallahue是公司董事会主席及行政总裁。在2011年1月加入公司之前，他担任瑞思迈公司（一家服务于睡眠呼吸障碍和呼吸市场的医疗器械公司）的董事、总裁兼首席执行官。 他于2003年1月加入瑞思迈，成为美洲公司的总裁兼首席运营官，并于2004年9月晋升至瑞思迈公司的总裁。在2008年1月被任命为公司总裁、首席执行官兼董事之前，他曾担任多个职务。在加入瑞思迈之前，从1998年1月至2002年12月，他在Nanogen公司（一家DNA研究和医疗诊断公司）担任多个职务，包括总裁兼首席财务官。在1998年之前他在仪器实验室、宝洁公司和通用电气公司担任各类营销、销售和财务职位。他是Volcano公司的董事。在过往五年中， 他还担任瑞思迈的董事。
Kieran T. Gallahue,Other Current Public Company Directorships:Envista Holdings Corporation, since 2019;Chair of the Nominating and Governance Committee, since 2019.Other Public Company Directorships Previously Held:Arena Pharmaceuticals, Inc., from 2018 to 2022;Member of the Audit Committee, from 2018 to 2022;Intersect ENT, Inc., from 2015 to 2022;Chairman of the Board, from 2020 to 2022;Member of the Audit Committee, from 2015 to 2022;CareFusion Corporation, from 2011 to 2015;Volcano Corporation, from 2007 to 2015;ResMed, Inc., from 2008 to 2011.Select Professional Experience and Highlights:CareFusion Corporation, a global medical technology company (acquired by Becton, Dickinson and Company in March 2015);Chairman and Chief Executive Officer, from 2011 until his retirement in 2015;ResMed, Inc. Chief Executive Officer, from 2008 to 2011;President, from 2004 to 2011;President and Chief Operating Officer, Americas, from 2003 to 2004.Nanogen, Inc. Various positions, including President and Chief Financial Officer, from 1998 to 2002;Prior to 1998, various marketing, sales, and financial positions within Instrumentation Laboratory, the Procter & Gamble Company, and the General Electric Company.Served on the Board and Executive Committee, and as Chairman of the International Committee and Treasurer of Advanced Medical Technology Association (AdvaMed). - Kieran T. Gallahue是公司董事会主席及行政总裁。在2011年1月加入公司之前，他担任瑞思迈公司（一家服务于睡眠呼吸障碍和呼吸市场的医疗器械公司）的董事、总裁兼首席执行官。 他于2003年1月加入瑞思迈，成为美洲公司的总裁兼首席运营官，并于2004年9月晋升至瑞思迈公司的总裁。在2008年1月被任命为公司总裁、首席执行官兼董事之前，他曾担任多个职务。在加入瑞思迈之前，从1998年1月至2002年12月，他在Nanogen公司（一家DNA研究和医疗诊断公司）担任多个职务，包括总裁兼首席财务官。在1998年之前他在仪器实验室、宝洁公司和通用电气公司担任各类营销、销售和财务职位。他是Volcano公司的董事。在过往五年中， 他还担任瑞思迈的董事。
- Kieran T. Gallahue,Other Current Public Company Directorships:Envista Holdings Corporation, since 2019;Chair of the Nominating and Governance Committee, since 2019.Other Public Company Directorships Previously Held:Arena Pharmaceuticals, Inc., from 2018 to 2022;Member of the Audit Committee, from 2018 to 2022;Intersect ENT, Inc., from 2015 to 2022;Chairman of the Board, from 2020 to 2022;Member of the Audit Committee, from 2015 to 2022;CareFusion Corporation, from 2011 to 2015;Volcano Corporation, from 2007 to 2015;ResMed, Inc., from 2008 to 2011.Select Professional Experience and Highlights:CareFusion Corporation, a global medical technology company (acquired by Becton, Dickinson and Company in March 2015);Chairman and Chief Executive Officer, from 2011 until his retirement in 2015;ResMed, Inc. Chief Executive Officer, from 2008 to 2011;President, from 2004 to 2011;President and Chief Operating Officer, Americas, from 2003 to 2004.Nanogen, Inc. Various positions, including President and Chief Financial Officer, from 1998 to 2002;Prior to 1998, various marketing, sales, and financial positions within Instrumentation Laboratory, the Procter & Gamble Company, and the General Electric Company.Served on the Board and Executive Committee, and as Chairman of the International Committee and Treasurer of Advanced Medical Technology Association (AdvaMed).
- W. Anthony Vernon
-
W. Anthony Vernon，退休高管，2014年至今；Esteve董事-西班牙（2016年至今）；McKinsey & Company LLC高级顾问（2014年至今）。
W. Anthony Vernon,qualifications include (i) senior executive experience at a publicly traded multinational company, (ii) consumer marketing experience, (iii) a detailed knowledge of the food industry, (iv) strategic leadership of a large, complex, organization, and (v) experience in mergers and acquisitions. Mr. Vernon is a seasoned and successful former Chief Executive Officer who has led major consumer products goods businesses and companies. Most recently, Mr. Vernon served as the Chief Executive Officer of the Kraft Foods Group from 2012 to 2014 and remained with the company as a Senior Advisor and Executive Director until April 2015. He was the first CEO of the newly formed company when Kraft Foods split its snack and grocery divisions into two independent public companies. Mr. Vernon also served as Executive Vice President of Kraft Foods and President of North America from 2009 to 2012. Prior to joining Kraft, Mr. Vernon served as Healthcare Industry Partner of Ripplewood Holdings LLC, a private equity firm. He also held several leadership roles at Johnson & Johnson where he spent 23 years of his career managing some of the company's largest consumer brands including Tylenol, Motrin, Pepcid AC, Imodium and Splenda. Mr. Vernon also served as President of Centocor, a Johnson & Johnson biotechnology company. Mr. Vernon currently serves on the boards of Nuvation Bio Inc. and Novocure Limited. - W. Anthony Vernon，退休高管，2014年至今；Esteve董事-西班牙（2016年至今）；McKinsey & Company LLC高级顾问（2014年至今）。
- W. Anthony Vernon,qualifications include (i) senior executive experience at a publicly traded multinational company, (ii) consumer marketing experience, (iii) a detailed knowledge of the food industry, (iv) strategic leadership of a large, complex, organization, and (v) experience in mergers and acquisitions. Mr. Vernon is a seasoned and successful former Chief Executive Officer who has led major consumer products goods businesses and companies. Most recently, Mr. Vernon served as the Chief Executive Officer of the Kraft Foods Group from 2012 to 2014 and remained with the company as a Senior Advisor and Executive Director until April 2015. He was the first CEO of the newly formed company when Kraft Foods split its snack and grocery divisions into two independent public companies. Mr. Vernon also served as Executive Vice President of Kraft Foods and President of North America from 2009 to 2012. Prior to joining Kraft, Mr. Vernon served as Healthcare Industry Partner of Ripplewood Holdings LLC, a private equity firm. He also held several leadership roles at Johnson & Johnson where he spent 23 years of his career managing some of the company's largest consumer brands including Tylenol, Motrin, Pepcid AC, Imodium and Splenda. Mr. Vernon also served as President of Centocor, a Johnson & Johnson biotechnology company. Mr. Vernon currently serves on the boards of Nuvation Bio Inc. and Novocure Limited.
- Frederic H. Moll
-
Frederic H. Moll博士自2011年6月起任眼科机器人运营公司Auris Surgical Robotics公司董事长，自2012年8月起任该公司首席执行官。Moll博士于2002年9月联合创办了医疗机器人公司Hansen Medical公司，并任该公司首席执行官至2010年6月，担任该公司董事会董事至2012年5月。1995年11月，Moll博士联合创办了医疗设备公司Intuitive Surgical公司，任该公司首任首席执行官，之后直到2003年9月之前担任该公司副总裁及医学总监。1989年，Moll博士联合创办了医疗设备公司Origin Medsystems公司，该公司于1992年被Eli Lilly and Company公司收购，之后成为医疗设备公司Guidant公司旗下运营公司。直到1995年11月之前，Moll博士在Guidant公司外科设备部门任医学总监。Moll博士拥有伯克利加利福尼亚大学学士学位、斯坦福大学硕士学位及华盛顿大学医学院博士学位。
Frederic H. Moll.Dr. Moll has served as the Chairman of Auris Surgical Robotics, Inc., an ophthalmic robotics company, since June 2011 and has served as its Chief Executive Officer since August 2012. Dr. Moll co-founded Hansen Medical, Inc., a medical robotics company, in September 2002 served as its Chief Executive Officer through June 2010 and served on its board of directors through May 2012. In November 1995 Dr. Moll co-founded Intuitive Surgical, Inc., a medical device company, and served as its first Chief Executive Officer and, later, its Vice President and Medical Director until September 2003. In 1989 Dr. Moll co-founded Origin Medsystems, Inc., a medical device company, which later became an operating company within Guidant Corporation, a medical device company, following its acquisition by Eli Lilly and Company in 1992. Dr. Moll served as Medical Director of Guidant’s surgical device division until November 1995. Dr. Moll holds a B.A.from the University of California, Berkeley, an M.S. from Stanford University and an M.D. from the University of Washington School of Medicine. - Frederic H. Moll博士自2011年6月起任眼科机器人运营公司Auris Surgical Robotics公司董事长，自2012年8月起任该公司首席执行官。Moll博士于2002年9月联合创办了医疗机器人公司Hansen Medical公司，并任该公司首席执行官至2010年6月，担任该公司董事会董事至2012年5月。1995年11月，Moll博士联合创办了医疗设备公司Intuitive Surgical公司，任该公司首任首席执行官，之后直到2003年9月之前担任该公司副总裁及医学总监。1989年，Moll博士联合创办了医疗设备公司Origin Medsystems公司，该公司于1992年被Eli Lilly and Company公司收购，之后成为医疗设备公司Guidant公司旗下运营公司。直到1995年11月之前，Moll博士在Guidant公司外科设备部门任医学总监。Moll博士拥有伯克利加利福尼亚大学学士学位、斯坦福大学硕士学位及华盛顿大学医学院博士学位。
- Frederic H. Moll.Dr. Moll has served as the Chairman of Auris Surgical Robotics, Inc., an ophthalmic robotics company, since June 2011 and has served as its Chief Executive Officer since August 2012. Dr. Moll co-founded Hansen Medical, Inc., a medical robotics company, in September 2002 served as its Chief Executive Officer through June 2010 and served on its board of directors through May 2012. In November 1995 Dr. Moll co-founded Intuitive Surgical, Inc., a medical device company, and served as its first Chief Executive Officer and, later, its Vice President and Medical Director until September 2003. In 1989 Dr. Moll co-founded Origin Medsystems, Inc., a medical device company, which later became an operating company within Guidant Corporation, a medical device company, following its acquisition by Eli Lilly and Company in 1992. Dr. Moll served as Medical Director of Guidant’s surgical device division until November 1995. Dr. Moll holds a B.A.from the University of California, Berkeley, an M.S. from Stanford University and an M.D. from the University of Washington School of Medicine.
- Lisa D. Earnhardt
-
Lisa D. Earnhardt从2008年3月开始担任Abbott Laboratories 总裁兼首席执行官，并担任董事，加入Abbott Laboratories 前，从2006年6月到2008年1月，Earnhardt女士担任波士顿科技公司（Boston Scientific）的心脏病外科手术部门的总裁直到其被出售给洁定集团（Getinge Group），前者以前叫美国佳滕公司（Guidant Corporation）或Guidant。从1996年8月到2006年4月，Earnhardt女士在Guidant任职，担任多个销售与市场部的领导职位。Earnhardt女士从2011年开始担任Kensey Nash的董事直到其于2012年被Royal DSM NA收购，前者是一家上市公司，她在该公司担任董事会的提名与治理和审计委员会委员。Earnhardt女士担任凯洛格商学院校友理事会（Kellogg Alumni Council）的主席。Earnhardt女士在西北大学凯洛格管理学院（Northwestern’s Kellogg School of Management ）获得工商管理硕士学位，并在斯坦福大学（Stanford University）获得工业工程理学士学位。
Lisa D. Earnhardt,2023 to present — Executive Vice President and Group President, Medical Devices.2019 to 2023 — Executive Vice President, Medical Devices.2008 to 2019 — President, CEO, and Director, Intersect ENT (a medical technology company focused on developing treatments for ear, nose and throat conditions).Elected Corporate Officer — 2019. - Lisa D. Earnhardt从2008年3月开始担任Abbott Laboratories 总裁兼首席执行官，并担任董事，加入Abbott Laboratories 前，从2006年6月到2008年1月，Earnhardt女士担任波士顿科技公司（Boston Scientific）的心脏病外科手术部门的总裁直到其被出售给洁定集团（Getinge Group），前者以前叫美国佳滕公司（Guidant Corporation）或Guidant。从1996年8月到2006年4月，Earnhardt女士在Guidant任职，担任多个销售与市场部的领导职位。Earnhardt女士从2011年开始担任Kensey Nash的董事直到其于2012年被Royal DSM NA收购，前者是一家上市公司，她在该公司担任董事会的提名与治理和审计委员会委员。Earnhardt女士担任凯洛格商学院校友理事会（Kellogg Alumni Council）的主席。Earnhardt女士在西北大学凯洛格管理学院（Northwestern’s Kellogg School of Management ）获得工商管理硕士学位，并在斯坦福大学（Stanford University）获得工业工程理学士学位。
- Lisa D. Earnhardt,2023 to present — Executive Vice President and Group President, Medical Devices.2019 to 2023 — Executive Vice President, Medical Devices.2008 to 2019 — President, CEO, and Director, Intersect ENT (a medical technology company focused on developing treatments for ear, nose and throat conditions).Elected Corporate Officer — 2019.
- Dana G. Mead, Jr.
-
Dana G. Mead, Jr.，自2008年7月起担任董事会成员。Mead先生于2019年5月至2021年2月担任HeartFlow，Inc.的首席执行官兼总裁，HeartFlow，Inc.是一家改变心脏病诊断和治疗方式的数字健康公司。2016年至2019年5月，Mead先生担任Beaver-Visitec International，Inc.的首席执行官兼总裁，Beaver-Visitec International，Inc.是一家外科手术设备开发商和制造商。从2005年到2016年，Mead先生在风险投资公司Kleiner Perkins Caufield & Byers担任合伙人。除了在董事会任职外，Mead先生自2015年6月起担任医疗技术公司Intersect ENT，Inc.的董事会成员，自2008年起担任Pulmonx Corporation的董事会成员。2011年5月至2016年12月，Mead先生在远程健康公司Teladoc, Inc.的董事会任职。Mead先生拥有拉法叶学院的学士学位和南加州大学的工商管理硕士学位。
Dana G. Mead, Jr.,served as the Chief Executive Officer, President and director of HeartFlow, Inc., a medical technology company. From November 2016 to May 2019, Mr. Mead served as President and Chief Executive Officer of Beaver-Visitec International, Inc., a surgical device developer and manufacturer. From June 2005 to November 2016, Mr. Mead served as a partner at Kleiner Perkins Caufield & Byers, a venture capital investment firm. In addition to serving on Pulmonx Corporation Board of Directors, Mr. Mead has served on the board of directors of Inari Medical, Inc. since October 2021 and the board of directors of Inspire Medical Systems since July 2008, where he serves on its audit committee. Mr. Mead also served on the board of directors of Inari Medical, Inc. from October 2021 until its sale to Stryker in February 2025 and Intersect ENT, Inc. from January 2006 until its sale to Medtronic, Inc. in May 2022. Mr. Mead holds a B.A. from Lafayette College and an M.B.A. from the University of Southern California. - Dana G. Mead, Jr.，自2008年7月起担任董事会成员。Mead先生于2019年5月至2021年2月担任HeartFlow，Inc.的首席执行官兼总裁，HeartFlow，Inc.是一家改变心脏病诊断和治疗方式的数字健康公司。2016年至2019年5月，Mead先生担任Beaver-Visitec International，Inc.的首席执行官兼总裁，Beaver-Visitec International，Inc.是一家外科手术设备开发商和制造商。从2005年到2016年，Mead先生在风险投资公司Kleiner Perkins Caufield & Byers担任合伙人。除了在董事会任职外，Mead先生自2015年6月起担任医疗技术公司Intersect ENT，Inc.的董事会成员，自2008年起担任Pulmonx Corporation的董事会成员。2011年5月至2016年12月，Mead先生在远程健康公司Teladoc, Inc.的董事会任职。Mead先生拥有拉法叶学院的学士学位和南加州大学的工商管理硕士学位。
- Dana G. Mead, Jr.,served as the Chief Executive Officer, President and director of HeartFlow, Inc., a medical technology company. From November 2016 to May 2019, Mr. Mead served as President and Chief Executive Officer of Beaver-Visitec International, Inc., a surgical device developer and manufacturer. From June 2005 to November 2016, Mr. Mead served as a partner at Kleiner Perkins Caufield & Byers, a venture capital investment firm. In addition to serving on Pulmonx Corporation Board of Directors, Mr. Mead has served on the board of directors of Inari Medical, Inc. since October 2021 and the board of directors of Inspire Medical Systems since July 2008, where he serves on its audit committee. Mr. Mead also served on the board of directors of Inari Medical, Inc. from October 2021 until its sale to Stryker in February 2025 and Intersect ENT, Inc. from January 2006 until its sale to Medtronic, Inc. in May 2022. Mr. Mead holds a B.A. from Lafayette College and an M.B.A. from the University of Southern California.
- Casey M. Tansey
-
Casey M. Tansey，自2010年8月起担任董事会成员。自2005年起，他担任风险投资公司U.S. Venture Partners的普通合伙人。从2001年到2004年，Tansey先生担任医疗设备公司Epicor Medical的首席执行官兼总裁。在加入Epicor Medical之前，Tansey先生是医疗设备公司Heartport，Inc.的首席执行官兼总裁，该公司现在是强生公司家族的一部分。在此之前，他在医疗技术公司Baxter Edward的心血管部门工作了近十年，担任过多个销售和营销职位。Tansey先生目前在Inspire Medical Systems, Inc.（纽约证券交易所代码：INSP）董事会任职，并担任组织和薪酬委员会成员，此前曾于2006年至2017年在Intersect ENT，Inc.董事会任职。他还担任U.S. Venture Partners多家私营公司投资组合的董事会成员，包括Cagent Vascular Inc.、HighLife Medical Inc.、Luminopia，Inc.、MicroTransponder Inc.、Neochord，Inc.、Neuros Medical，Inc.、ShiraTronics，Inc.和Shoulder Innovations。Tansey先生获得了圣母大学的学士学位和工商管理硕士学位。
Casey M. Tansey,has served as a member of board of directors since August 2010. Since 2005, he has served as a General Partner of U.S. Venture Partners, a venture capital firm. From 2001 until 2004, Mr. Tansey served as the Chief Executive Officer and President of Epicor Medical, a medical device company. Prior to Epicor Medical, Mr. Tansey was Chief Executive Officer and President of Heartport, Inc., a medical device company, which is now part of the Johnson & Johnson family of companies. Prior to that, he was with the cardiovascular division at Baxter Edward, a medical technology company, for nearly ten years, holding various sales and marketing positions. Mr. Tansey currently serves on the board of directors and as a member of the organization and compensation committee of Inspire Medical Systems, Inc. (NYSE: INSP) and previously served on the board of directors of Intersect ENT, Inc. from 2006 until 2017. He also serves on the board of directors for a number of U.S. Venture Partners' portfolio of private companies, including Cagent Vascular Inc., HighLife Medical Inc., Luminopia, Inc., MicroTransponder Inc., Neochord, Inc., Neuros Medical, Inc., ShiraTronics, Inc. and Shoulder Innovations. Mr. Tansey received a B.S. and an M.B.A. from the Notre Dame De Namur University. - Casey M. Tansey，自2010年8月起担任董事会成员。自2005年起，他担任风险投资公司U.S. Venture Partners的普通合伙人。从2001年到2004年，Tansey先生担任医疗设备公司Epicor Medical的首席执行官兼总裁。在加入Epicor Medical之前，Tansey先生是医疗设备公司Heartport，Inc.的首席执行官兼总裁，该公司现在是强生公司家族的一部分。在此之前，他在医疗技术公司Baxter Edward的心血管部门工作了近十年，担任过多个销售和营销职位。Tansey先生目前在Inspire Medical Systems, Inc.（纽约证券交易所代码：INSP）董事会任职，并担任组织和薪酬委员会成员，此前曾于2006年至2017年在Intersect ENT，Inc.董事会任职。他还担任U.S. Venture Partners多家私营公司投资组合的董事会成员，包括Cagent Vascular Inc.、HighLife Medical Inc.、Luminopia，Inc.、MicroTransponder Inc.、Neochord，Inc.、Neuros Medical，Inc.、ShiraTronics，Inc.和Shoulder Innovations。Tansey先生获得了圣母大学的学士学位和工商管理硕士学位。
- Casey M. Tansey,has served as a member of board of directors since August 2010. Since 2005, he has served as a General Partner of U.S. Venture Partners, a venture capital firm. From 2001 until 2004, Mr. Tansey served as the Chief Executive Officer and President of Epicor Medical, a medical device company. Prior to Epicor Medical, Mr. Tansey was Chief Executive Officer and President of Heartport, Inc., a medical device company, which is now part of the Johnson & Johnson family of companies. Prior to that, he was with the cardiovascular division at Baxter Edward, a medical technology company, for nearly ten years, holding various sales and marketing positions. Mr. Tansey currently serves on the board of directors and as a member of the organization and compensation committee of Inspire Medical Systems, Inc. (NYSE: INSP) and previously served on the board of directors of Intersect ENT, Inc. from 2006 until 2017. He also serves on the board of directors for a number of U.S. Venture Partners' portfolio of private companies, including Cagent Vascular Inc., HighLife Medical Inc., Luminopia, Inc., MicroTransponder Inc., Neochord, Inc., Neuros Medical, Inc., ShiraTronics, Inc. and Shoulder Innovations. Mr. Tansey received a B.S. and an M.B.A. from the Notre Dame De Namur University.
高管简历
中英对照 | 中文 | 英文- Charles S. McKhann
Charles S. McKhann，2015年2月起，担任本公司的首席商业官。2013年12月至2015年1月，他在Monitor Deloitte的生命科学策略顾问部门担任总监，这是一个全球性的医疗保健与生命科学咨询公司，曾负责与全球医疗器械制造商合作，制定和实施创新的增长策略。2010年6月至2012年10月，他担任 Apnex Medical, Inc的总裁、首席执行官，这是一个医疗器械初创企业；他曾负责一个新型疗法的开发、临床试验、商业规划，适用于阻塞性睡眠呼吸暂停症患者。2007年1月至2010年4月，他曾在 Boston Scientific的心脏外科业务部担任过营销副总裁、血管重建总经理，以及心律管理业务部的全球营销副总裁，负责全球范围内的营销、产品上市规划与实施。
Charles S. McKhann has served as our Chief Commercial Officer since February 2015. From December 2013 to January 2015 Mr. McKhann served as a Director in the Life Sciences Strategy consulting practice at Monitor Deloitte, a global healthcare and life sciences consulting firm, where he was responsible for working with global medical device manufacturers to create and execute innovative growth strategies. From June 2010 to October 2012 Mr. McKhann served as President and Chief Executive Officer of Apnex Medical, Inc., a medical device start up, where he was responsible for leading the development, clinical trials and commercial planning for an innovative treatment for patients suffering from obstructive sleep apnea. From January 2007 to April 2010 Mr. McKhann served as Vice President of Marketing and General Manager of the Revascularization Franchise for the Cardiac Surgery unit and as Vice President of Worldwide Marketing for the Cardiac Rhythm Management unit of Boston Scientific, where he was responsible for global marketing and product launch planning and execution.- Charles S. McKhann，2015年2月起，担任本公司的首席商业官。2013年12月至2015年1月，他在Monitor Deloitte的生命科学策略顾问部门担任总监，这是一个全球性的医疗保健与生命科学咨询公司，曾负责与全球医疗器械制造商合作，制定和实施创新的增长策略。2010年6月至2012年10月，他担任 Apnex Medical, Inc的总裁、首席执行官，这是一个医疗器械初创企业；他曾负责一个新型疗法的开发、临床试验、商业规划，适用于阻塞性睡眠呼吸暂停症患者。2007年1月至2010年4月，他曾在 Boston Scientific的心脏外科业务部担任过营销副总裁、血管重建总经理，以及心律管理业务部的全球营销副总裁，负责全球范围内的营销、产品上市规划与实施。
- Charles S. McKhann has served as our Chief Commercial Officer since February 2015. From December 2013 to January 2015 Mr. McKhann served as a Director in the Life Sciences Strategy consulting practice at Monitor Deloitte, a global healthcare and life sciences consulting firm, where he was responsible for working with global medical device manufacturers to create and execute innovative growth strategies. From June 2010 to October 2012 Mr. McKhann served as President and Chief Executive Officer of Apnex Medical, Inc., a medical device start up, where he was responsible for leading the development, clinical trials and commercial planning for an innovative treatment for patients suffering from obstructive sleep apnea. From January 2007 to April 2010 Mr. McKhann served as Vice President of Marketing and General Manager of the Revascularization Franchise for the Cardiac Surgery unit and as Vice President of Worldwide Marketing for the Cardiac Rhythm Management unit of Boston Scientific, where he was responsible for global marketing and product launch planning and execution.
- David A. Lehman
David A. Lehman，曾一直担任我们的总法律顾问（2016年2月以来）。2003年5月至2015年10月，他最近担任Thoratec Corporation（机械循环支持公司）的高级副总裁、总法律顾问和秘书，在那里他负责管理Thoratec公司的内部法律和医疗合规功能。
David A. Lehman has served as our General Counsel since February 2016. From May 2003 to October 2015 Mr. Lehman served most recently as Senior Vice President, General Counsel and Secretary of Thoratec Corporation, or Thoratec, a mechanical circulatory support company, where he was responsible for managing Thoratec’s internal legal and healthcare compliance functions.- David A. Lehman，曾一直担任我们的总法律顾问（2016年2月以来）。2003年5月至2015年10月，他最近担任Thoratec Corporation（机械循环支持公司）的高级副总裁、总法律顾问和秘书，在那里他负责管理Thoratec公司的内部法律和医疗合规功能。
- David A. Lehman has served as our General Counsel since February 2016. From May 2003 to October 2015 Mr. Lehman served most recently as Senior Vice President, General Counsel and Secretary of Thoratec Corporation, or Thoratec, a mechanical circulatory support company, where he was responsible for managing Thoratec’s internal legal and healthcare compliance functions.
- Jeryl L. Hilleman
Jeryl L. Hilleman，她一直担任我们董事会的成员（2005年1月以来）。她是Ocera Therapeutics公司（临床阶段生物制药公司）的首席财务官。2013年9月加入Ocera公司之前，她负责为生物技术和清洁技术公司提供独立财务和战略咨询。从2008年1月到2012年5月，她担任Amyris Biotechnologies公司（公司专门从事合成生物学）的首席财务官。加入Amyris公司之前，她曾担任Symyx Technologies公司（公司专业从事高通量实验材料的发现）的执行副总裁兼首席财务官（从1997年到2007年6月）。1997年加入Symyx公司之前，她曾担任两个公共生物技术公司的财务副总裁兼首席财务官，即Geron Corporation和Cytel Corporation（后于1999年与Epimmune公司合并）。她持有Brown University的学士学位，以及the Wharton Graduate School of Business的工商管理硕士学位。
Jeryl L. Hilleman has been a member of our board of directors since January 2005. Since June 2014 she has served as chief financial officer at Intersect ENT, Inc., a medical device company. Prior to joining Intersect ENT, from September 2013 to June 2014 Ms. Hilleman was chief financial officer, chief accounting officer and secretary of Ocera Therapeutics, Inc., a biopharmaceutical company. From May 2012 to September 2013 Ms. Hilleman provided independent financial and strategic consulting for biotech and clean-tech companies. From January 2008 to May 2012 she was chief financial officer of Amyris Biotechnologies, Inc., a company specializing in synthetic biology. Prior to joining Amyris, she was executive vice president and chief financial officer of Symyx Technologies, Inc., a company specializing in high-throughput experimentation for the discovery of materials, from 1997 to June 2007. Prior to that, from 1997 to 1999 Ms. Hilleman served as vice president finance and chief financial officer of two public biotechnology companies, Geron Corporation and Cytel Corporation, which merged with Epimmune Inc. in 1999. Ms. Hilleman received an A.B. from Brown University and an M.B.A. from the Wharton Graduate School of Business.- Jeryl L. Hilleman，她一直担任我们董事会的成员（2005年1月以来）。她是Ocera Therapeutics公司（临床阶段生物制药公司）的首席财务官。2013年9月加入Ocera公司之前，她负责为生物技术和清洁技术公司提供独立财务和战略咨询。从2008年1月到2012年5月，她担任Amyris Biotechnologies公司（公司专门从事合成生物学）的首席财务官。加入Amyris公司之前，她曾担任Symyx Technologies公司（公司专业从事高通量实验材料的发现）的执行副总裁兼首席财务官（从1997年到2007年6月）。1997年加入Symyx公司之前，她曾担任两个公共生物技术公司的财务副总裁兼首席财务官，即Geron Corporation和Cytel Corporation（后于1999年与Epimmune公司合并）。她持有Brown University的学士学位，以及the Wharton Graduate School of Business的工商管理硕士学位。
- Jeryl L. Hilleman has been a member of our board of directors since January 2005. Since June 2014 she has served as chief financial officer at Intersect ENT, Inc., a medical device company. Prior to joining Intersect ENT, from September 2013 to June 2014 Ms. Hilleman was chief financial officer, chief accounting officer and secretary of Ocera Therapeutics, Inc., a biopharmaceutical company. From May 2012 to September 2013 Ms. Hilleman provided independent financial and strategic consulting for biotech and clean-tech companies. From January 2008 to May 2012 she was chief financial officer of Amyris Biotechnologies, Inc., a company specializing in synthetic biology. Prior to joining Amyris, she was executive vice president and chief financial officer of Symyx Technologies, Inc., a company specializing in high-throughput experimentation for the discovery of materials, from 1997 to June 2007. Prior to that, from 1997 to 1999 Ms. Hilleman served as vice president finance and chief financial officer of two public biotechnology companies, Geron Corporation and Cytel Corporation, which merged with Epimmune Inc. in 1999. Ms. Hilleman received an A.B. from Brown University and an M.B.A. from the Wharton Graduate School of Business.
- David A. Lehman
David A. Lehman，曾一直担任Intersect Ent, Inc.的总法律顾问（2016年2月以来）。他是Thoratec Corporation的高级副总裁、总法律顾问和秘书。2003年5月他加入Thoratec Corporation并担任副总裁和高级副总裁。2004年12月他被任命为秘书。2007年2月他成为高级副总裁。在加入我们之前的2000年6月到2003年5月，他担任 Brigade Corporation（提供业务流程外包服务的公司）的副总裁和总法律顾问。从1997年11月到2000年6月，他曾是Bio-Rad Laboratories, Inc.（诊断和生命科学产品的公司）的助理总法律顾问。在1997年11月之前，他曾在纽约和东京的Mitsubishi International Corporation法律部门任职超过7年。他的事业始于在律师事务所Hall, Dickler, Kent, Friedman and Wood担任联合律师。他获得圣地亚哥的加州大学（University of California）的政治科学学士学位和康奈尔大学（ Cornell University ）法学院的法学博士学位。
David A. Lehman joined Thoratec Corporation as Vice President and General Counsel in May 2003. Mr. Lehman was appointed as Secretary in December 2004 and became Senior Vice President in February 2007. Prior to joining us, Mr. Lehman served as Vice President and General Counsel of Brigade Corporation, a provider of business process outsourcing services, from June 2000 to May 2003. From November 1997 to June 2000 Mr. Lehman was Assistant General Counsel at Bio-Rad Laboratories, Inc., a diagnostic and life science products company. Prior to November 1997 Mr. Lehman was in the legal department of Mitsubishi International Corporation, in New York and Tokyo, for more than seven years. Mr. Lehman started his career as an associate attorney at the law firm of Hall, Dickler, Kent, Friedman and Wood. Mr. Lehman has a Bachelor of Arts in political science from the University of California, San Diego, and a Juris Doctor from Cornell University Law School.- David A. Lehman，曾一直担任Intersect Ent, Inc.的总法律顾问（2016年2月以来）。他是Thoratec Corporation的高级副总裁、总法律顾问和秘书。2003年5月他加入Thoratec Corporation并担任副总裁和高级副总裁。2004年12月他被任命为秘书。2007年2月他成为高级副总裁。在加入我们之前的2000年6月到2003年5月，他担任 Brigade Corporation（提供业务流程外包服务的公司）的副总裁和总法律顾问。从1997年11月到2000年6月，他曾是Bio-Rad Laboratories, Inc.（诊断和生命科学产品的公司）的助理总法律顾问。在1997年11月之前，他曾在纽约和东京的Mitsubishi International Corporation法律部门任职超过7年。他的事业始于在律师事务所Hall, Dickler, Kent, Friedman and Wood担任联合律师。他获得圣地亚哥的加州大学（University of California）的政治科学学士学位和康奈尔大学（ Cornell University ）法学院的法学博士学位。
- David A. Lehman joined Thoratec Corporation as Vice President and General Counsel in May 2003. Mr. Lehman was appointed as Secretary in December 2004 and became Senior Vice President in February 2007. Prior to joining us, Mr. Lehman served as Vice President and General Counsel of Brigade Corporation, a provider of business process outsourcing services, from June 2000 to May 2003. From November 1997 to June 2000 Mr. Lehman was Assistant General Counsel at Bio-Rad Laboratories, Inc., a diagnostic and life science products company. Prior to November 1997 Mr. Lehman was in the legal department of Mitsubishi International Corporation, in New York and Tokyo, for more than seven years. Mr. Lehman started his career as an associate attorney at the law firm of Hall, Dickler, Kent, Friedman and Wood. Mr. Lehman has a Bachelor of Arts in political science from the University of California, San Diego, and a Juris Doctor from Cornell University Law School.
- Lisa D. Earnhardt
Lisa D. Earnhardt从2008年3月开始担任Abbott Laboratories 总裁兼首席执行官，并担任董事，加入Abbott Laboratories 前，从2006年6月到2008年1月，Earnhardt女士担任波士顿科技公司（Boston Scientific）的心脏病外科手术部门的总裁直到其被出售给洁定集团（Getinge Group），前者以前叫美国佳滕公司（Guidant Corporation）或Guidant。从1996年8月到2006年4月，Earnhardt女士在Guidant任职，担任多个销售与市场部的领导职位。Earnhardt女士从2011年开始担任Kensey Nash的董事直到其于2012年被Royal DSM NA收购，前者是一家上市公司，她在该公司担任董事会的提名与治理和审计委员会委员。Earnhardt女士担任凯洛格商学院校友理事会（Kellogg Alumni Council）的主席。Earnhardt女士在西北大学凯洛格管理学院（Northwestern’s Kellogg School of Management ）获得工商管理硕士学位，并在斯坦福大学（Stanford University）获得工业工程理学士学位。
Lisa D. Earnhardt,2023 to present — Executive Vice President and Group President, Medical Devices.2019 to 2023 — Executive Vice President, Medical Devices.2008 to 2019 — President, CEO, and Director, Intersect ENT (a medical technology company focused on developing treatments for ear, nose and throat conditions).Elected Corporate Officer — 2019.- Lisa D. Earnhardt从2008年3月开始担任Abbott Laboratories 总裁兼首席执行官，并担任董事，加入Abbott Laboratories 前，从2006年6月到2008年1月，Earnhardt女士担任波士顿科技公司（Boston Scientific）的心脏病外科手术部门的总裁直到其被出售给洁定集团（Getinge Group），前者以前叫美国佳滕公司（Guidant Corporation）或Guidant。从1996年8月到2006年4月，Earnhardt女士在Guidant任职，担任多个销售与市场部的领导职位。Earnhardt女士从2011年开始担任Kensey Nash的董事直到其于2012年被Royal DSM NA收购，前者是一家上市公司，她在该公司担任董事会的提名与治理和审计委员会委员。Earnhardt女士担任凯洛格商学院校友理事会（Kellogg Alumni Council）的主席。Earnhardt女士在西北大学凯洛格管理学院（Northwestern’s Kellogg School of Management ）获得工商管理硕士学位，并在斯坦福大学（Stanford University）获得工业工程理学士学位。
- Lisa D. Earnhardt,2023 to present — Executive Vice President and Group President, Medical Devices.2019 to 2023 — Executive Vice President, Medical Devices.2008 to 2019 — President, CEO, and Director, Intersect ENT (a medical technology company focused on developing treatments for ear, nose and throat conditions).Elected Corporate Officer — 2019.
- Richard E. Kaufman
Richard E. Kaufman从2007年1月开始担任我司研发部与运营部的高级副总裁，并担任首席运营官。加入我司前，Kaufman先生担任雅培生物吸收性血管解决方案部的副总裁和总经理。从1998年到2006年，Kaufman先生担任过Guidant的几个研发与运营部的领导职位。在这之前，从1993年到1998年，Kaufman先生在麦格医疗技术公司（McGhan Medical）任职，开发整形手术领域的产品，从1990年到1993年，在英伯伦（IMPRA）任职，开发矫形和人造血管的产品。Kaufman先生在亚利桑那州立大学（Arizona State University）获得生物医学工程的理学士学位。
Richard E. Kaufman has served as our Senior Vice President of R&D and Operations and Chief Operating Officer since January 2007. Prior to joining us, Mr. Kaufman was the Vice President and General Manager of Abbott Bioabsorbable Vascular Solutions. Mr. Kaufman held several R&D and Operations leadership positions at Guidant from 1998 through 2006. Previously Mr. Kaufman worked at McGhan Medical from 1993 to 1998 developing products for the plastic surgery field and at IMPRA from 1990 to 1993 developing products for orthopedics and vascular grafts. Mr. Kaufman holds a B.S. in Biomedical Engineering from Arizona State University.- Richard E. Kaufman从2007年1月开始担任我司研发部与运营部的高级副总裁，并担任首席运营官。加入我司前，Kaufman先生担任雅培生物吸收性血管解决方案部的副总裁和总经理。从1998年到2006年，Kaufman先生担任过Guidant的几个研发与运营部的领导职位。在这之前，从1993年到1998年，Kaufman先生在麦格医疗技术公司（McGhan Medical）任职，开发整形手术领域的产品，从1990年到1993年，在英伯伦（IMPRA）任职，开发矫形和人造血管的产品。Kaufman先生在亚利桑那州立大学（Arizona State University）获得生物医学工程的理学士学位。
- Richard E. Kaufman has served as our Senior Vice President of R&D and Operations and Chief Operating Officer since January 2007. Prior to joining us, Mr. Kaufman was the Vice President and General Manager of Abbott Bioabsorbable Vascular Solutions. Mr. Kaufman held several R&D and Operations leadership positions at Guidant from 1998 through 2006. Previously Mr. Kaufman worked at McGhan Medical from 1993 to 1998 developing products for the plastic surgery field and at IMPRA from 1990 to 1993 developing products for orthopedics and vascular grafts. Mr. Kaufman holds a B.S. in Biomedical Engineering from Arizona State University.
- James Stambaugh
James Stambaugh从2006年10月开始担任我司临床与偿付部副总裁。加入我司前，从2005年3月到2006年10月，Stambaugh先生担任Guidant的血管介入部门的临床手术部总监。担任临床手术部总监前，Stambaugh先生担任过Guidant的临床前、临床与监管环境部门的多个职位。Stambaugh先生在戴维斯的加利福尼亚大学（University of California）获得化学理学学士学位。
James Stambaugh has served as our Vice President of Clinical and Reimbursement since October 2006. Prior to joining us, Mr. Stambaugh served as Director of Clinical Operations at Guidant’s Vascular Intervention division, from March 2005 to October 2006. Prior to serving as Director of Clinical Operations Mr. Stambaugh held various positions at Guidant within the pre-clinical, clinical and regulatory environment. Mr. Stambaugh holds a B.S. in Chemistry from the University of California at Davis.- James Stambaugh从2006年10月开始担任我司临床与偿付部副总裁。加入我司前，从2005年3月到2006年10月，Stambaugh先生担任Guidant的血管介入部门的临床手术部总监。担任临床手术部总监前，Stambaugh先生担任过Guidant的临床前、临床与监管环境部门的多个职位。Stambaugh先生在戴维斯的加利福尼亚大学（University of California）获得化学理学学士学位。
- James Stambaugh has served as our Vice President of Clinical and Reimbursement since October 2006. Prior to joining us, Mr. Stambaugh served as Director of Clinical Operations at Guidant’s Vascular Intervention division, from March 2005 to October 2006. Prior to serving as Director of Clinical Operations Mr. Stambaugh held various positions at Guidant within the pre-clinical, clinical and regulatory environment. Mr. Stambaugh holds a B.S. in Chemistry from the University of California at Davis.
- Amy Wolbeck
Amy Wolbeck从2011年1月开始担任我司法规事务与质量部的副总裁，从2009年1月到2011年1月，担任我司法规事务部的总监。加入我司前，Wolbeck女士担任索诺玛骨科产品（Sonoma Orthopedic Products）的法规事务与质量保证部的总监。从1998年至2007年，Wolbeck女士担任美敦力公司（Medtronic）的多个职位，包括担任美敦力公司的心血管部门的法规事务部总监，并担任美敦力血管公司（ Medtronic Vascular）的质量部总监。Wolbeck女士在阿默斯特大学（University of Massachusetts at Amherst）获得机械工程理学学士学位。
Amy Wolbeck has served as our Vice President, Regulatory Affairs and Quality since January 2011 and served as our Director of Regulatory Affairs from January 2009 to January 2011. Prior to joining us, Ms. Wolbeck was the Director of Regulatory Affairs and Quality Assurance at Sonoma Orthopedic Products. Ms. Wolbeck served in various roles at Medtronic from 1998-2007 including Director of Regulatory Affairs within Medtronic’s Cardiovascular Division and Director of Quality for Medtronic Vascular. Ms. Wolbeck holds a B.S. in Mechanical Engineering from the University of Massachusetts at Amherst.- Amy Wolbeck从2011年1月开始担任我司法规事务与质量部的副总裁，从2009年1月到2011年1月，担任我司法规事务部的总监。加入我司前，Wolbeck女士担任索诺玛骨科产品（Sonoma Orthopedic Products）的法规事务与质量保证部的总监。从1998年至2007年，Wolbeck女士担任美敦力公司（Medtronic）的多个职位，包括担任美敦力公司的心血管部门的法规事务部总监，并担任美敦力血管公司（ Medtronic Vascular）的质量部总监。Wolbeck女士在阿默斯特大学（University of Massachusetts at Amherst）获得机械工程理学学士学位。
- Amy Wolbeck has served as our Vice President, Regulatory Affairs and Quality since January 2011 and served as our Director of Regulatory Affairs from January 2009 to January 2011. Prior to joining us, Ms. Wolbeck was the Director of Regulatory Affairs and Quality Assurance at Sonoma Orthopedic Products. Ms. Wolbeck served in various roles at Medtronic from 1998-2007 including Director of Regulatory Affairs within Medtronic’s Cardiovascular Division and Director of Quality for Medtronic Vascular. Ms. Wolbeck holds a B.S. in Mechanical Engineering from the University of Massachusetts at Amherst.